Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in biologic-naive active ankylosing spondylitis
NCT04483700Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of filgotinib in ankylosing spondylitis (AS), sponsored by Gilead Sciences. Planned start Dec 2020; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04483700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483700.